Get the Stockscreener App
2.6797
27.18%
-0.9903
Salarius Pharmaceuticals Inc stock is traded at $2.6797, with a volume of 1.12M.
It is down -27.18% in the last 24 hours and up +81.81% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$3.67
Open:
$3.01
24h Volume:
1.12M
Relative Volume:
0.52
Market Cap:
$5.29M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.4174
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+56.28%
1M Performance:
+81.81%
6M Performance:
+34.97%
1Y Performance:
-45.24%
1-Day Range:
$2.55
$3.39
1-Week Range:
$1.55
$7.20
52-Week Range:
$1.22
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
2.65 | 5.29M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.24 | 106.45B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
708.51 | 78.78B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
673.65 | 40.09B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.88 | 33.16B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
116.48 | 27.70B | 3.30B | -501.07M | 1.03B | -2.1146 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Houston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatment - The Business Journals
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On MondayHere's Why - Yahoo Finance
Stock market news: Phio Pharmaceuticals +296.88%, Salarius Pharmaceuticals +153.67% among top gainers during mid day trading - Business Upturn
FDA approves Zeiss Medical Technology’s MEL 90 excimer laser - Yahoo! Voices
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Xiaohongshu, China's answer to Instagram, hits no. 1 on the App Store as TikTok faces US shutdown - Yahoo! Voices
Gilead and LEO Pharma link on programmes for inflammatory conditions - Yahoo! Voices
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion - Yahoo Finance
Stock market today: Phio Pharmaceuticals +289.93%, Sage Therapeutics +34.95% among the top gainers in early trading - Business Upturn
Stock market today: Kairos Pharma saw rise of 130.20% and Salarius Pharmaceuticals was up by 180.52% in early trading - Business Upturn
Salarius Pharmaceuticals Merges with Decoy Therapeutics - TipRanks
Salarius Pharmaceuticals to Merge with Decoy Therapeutics - MarketWatch
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement - The Manila Times
Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results - The Manila Times
Salarius, Decoy Therapeutics enter definitive merger agreement - TipRanks
Salarius Pharma Merges with AI Drug Designer Decoy Therapeutics, Plans Pan-Coronavirus Drug - StockTitan
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 - Yahoo Finance
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025 - Yahoo Finance
Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media? - Yahoo Finance
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Ewing Sarcoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing - Yahoo Finance
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance
Salarius Announces Allowance of New European Patent Covering Seclidemstat - Marketscreener.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading 1.3% Higher – Time to Buy? - Defense World
Will TG Therapeutics, Inc. (TGTX) Make You Rich In 2025? - Yahoo Finance
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Yahoo Finance
SLRX stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Zomedica Strengthens Leadership: Industry Veteran with 30+ Years Experience Named New CFO - StockTitan
SLRX stock touches 52-week low at $1.24 amid market challenges - Investing.com
Salarius Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, - openPR
Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Yahoo Finance
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Yahoo Finance
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - Yahoo Finance
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Yahoo Finance
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Yahoo Finance
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Yahoo Finance
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference - Yahoo Finance
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Yahoo Finance
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.37%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):